1. Home
  2. SCZM vs SLN Comparison

SCZM vs SLN Comparison

Compare SCZM & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Santacruz Silver Mining Ltd. Common Shares

SCZM

Santacruz Silver Mining Ltd. Common Shares

HOLD

Current Price

$8.88

Market Cap

585.2M

Sector

N/A

ML Signal

HOLD

Logo Silence Therapeutics Plc American Depository Share

SLN

Silence Therapeutics Plc American Depository Share

HOLD

Current Price

$11.51

Market Cap

678.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCZM
SLN
Founded
N/A
1994
Country
Canada
United Kingdom
Employees
455
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
585.2M
678.0M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
SCZM
SLN
Price
$8.88
$11.51
Analyst Decision
Strong Buy
Buy
Analyst Count
1
5
Target Price
$12.00
$42.60
AVG Volume (30 Days)
400.4K
647.9K
Earning Date
05-29-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$559,000.00
Revenue This Year
$79.38
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$14.27
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.61
$4.19
52 Week High
$17.65
$17.58

Technical Indicators

Market Signals
Indicator
SCZM
SLN
Relative Strength Index (RSI) 50.32 42.56
Support Level $8.55 $4.70
Resistance Level $10.33 $15.28
Average True Range (ATR) 0.50 0.58
MACD -0.12 -0.23
Stochastic Oscillator 39.79 10.46

Price Performance

Historical Comparison
SCZM
SLN

About SCZM Santacruz Silver Mining Ltd. Common Shares

Santacruz Silver Mining Ltd is engaged in the operation, acquisition, exploration, and development of mineral properties in Latin America, with a primary focus on silver and zinc, including lead and copper. The company earns the majority of its revenue from Zinc and Silver. The company's reportable operating segments are the Bolivar mine and processing plant, the Porco mine and processing plant, the Caballo Blanco Group, San Lucas, Zimapa mine and processing plant, and Corporate and Other activities. Key revenue is generated from Zimapan.

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

Share on Social Networks: